Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

This study tests mosunetuzumab — a bispecific antibody that brings immune T-cells and cancer B-cells together to kill the cancer — at a lower dose than standard, in people who have never been treated for indolent (slow-growing) B-cell lymphoma, a type of blood cancer. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with a slow-growing B-cell non-Hodgkin lymphoma (such as follicular lymphoma grade 1–3A, or marginal zone lymphoma) - You have never received treatment for lymphoma (or only had a peptide-based vaccine) - Your lymphoma meets criteria requiring treatment **You may NOT be eligible if...** - You have previously received chemotherapy, immunotherapy, or radiation for lymphoma - You have an aggressive (fast-growing) type of lymphoma - You have active autoimmune disease requiring treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.